研究者
J-GLOBAL ID:201301096362306785   更新日: 2024年01月30日

吉村 健一

YOSHIMURA KENICHI
所属機関・部署:
職名: 教授
その他の所属(所属・部署名・職名) (1件):
  • 神戸大学  客員教授
競争的資金等の研究課題 (11件):
  • 2021 - 2024 国際共同臨床研究データの近代的構築と発展 ~最新の情報工学技術の融合による挑戦
  • 2019 - 2023 がん臨床試験における患者の意思決定支援のための学習プログラム開発と実践知の可視化
  • 2016 - 2020 逐次治療の評価における重み付き並び替え法を用いた新規推定法の開発
  • 2016 - 2020 小児がん研究グループによる小児肝がんの海外診療状況調査と国際共同臨床研究基盤整備
  • 2016 - 2019 進行消化器癌に対するα線核種内照射療法による治療戦略の確立
全件表示
論文 (146件):
  • Kazushige Wakuda, Hiroyuki Yamaguchi, Hirotsugu Kenmotsu, Minoru Fukuda, Kentaro Ito, Yuko Tsuchiya-Kawano, Kentaro Tanaka, Taishi Harada, Yuki Nakatani, Satoru Miura, et al. A Phase 2 Single-Arm Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis NSCLC: Results for the First-Line Cohort of the OCEAN Study (LOGIK 1603/WJOG 9116L). JTO clinical and research reports. 2023. 4. 12. 100587-100587
  • Yukinori Ozaki, Junji Tsurutani, Toru Mukohara, Tsutomu Iwasa, Masato Takahashi, Yuko Tanabe, Hidetaka Kawabata, Norikazu Masuda, Manabu Futamura, Hironobu Minami, et al. Data of programmed death-ligand 1 expression and VEGF: Nivolumab, bevacizumab and paclitaxel For HER2-negative metastatic breast cancer. Data in brief. 2022. 45. 108558-108558
  • Hiroshi Wakabayashi, Anri Inaki, Kenichi Yoshimura, Toshinori Murayama, Yasuhito Imai, Tetsuya Higuchi, Megumi Jinguji, Tohru Shiga, Seigo Kinuya. Author Correction: A phase I clinical trial for [131I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma. Scientific Reports. 2022. 12. 1
  • Yoshinobu Yamamoto, Naohiro Yoshida, Tomonori Yano, Takahiro Horimatsu, Noriya Uedo, Noboru Kawata, Hiromitsu Kanzaki, Shinichiro Hori, Kenshi Yao, Seiichiro Abe, et al. Assessment of Outcomes From 1-Year Surveillance After Detection of Early Gastric Cancer Among Patients at High Risk in Japan. JAMA Network Open. 2022. 5. 8. e2227667-e2227667
  • Yukinori Ozaki, Junji Tsurutani, Toru Mukohara, Tsutomu Iwasa, Masato Takahashi, Yuko Tanabe, Hidetaka Kawabata, Norikazu Masuda, Manabu Futamura, Hironobu Minami, et al. Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B). European journal of cancer (Oxford, England : 1990). 2022. 171. 193-202
もっと見る
MISC (50件):
  • Jun Masuda, Junji Tsurutani, Norikazu Masuda, Yuko Tanabe, Tsutomu Iwasa, Masato Takahashi, Manabu Futamura, Koji Matsumoto, Kenjiro Aogi, Hiroji Iwata, et al. Phase II study of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR+, HER2-metastatic breast cancer: WJOG11418B NEWFLAME trial. CANCER RESEARCH. 2021. 81. 4
  • Yukinori Ozaki, Shigehisa Kitano, Junji Tsurutani, Tsutomu Iwasa, Masato Takahashi, Toru Mukohara, Norikazu Masuda, Manabu Futamura, Hironobu Minami, Koji Matsumoto, et al. Immunological analysis of the combination therapy of nivolumab, paclitaxel and bevacizumab in patients with HER2negative MBC in NEWBEAT trial (WJOG9917BTR). CANCER RESEARCH. 2021. 81. 4
  • Hiroko Masuda, Tsutomu Iwasa, Toru Mukohara, Shinya Tokunaga, Koji Matsumoto, Naoki Niikura, Yasuaki Sagara, Yasuo Miyoshi, Akihiko Shimomura, Masato Takahashi, et al. Phase II study of trimebutine maleate and probiotics for abemaciclib-induced diarrhea in patients with ER-positive and HER2-negative advanced breast cancer (MERMAID) WJOG11318B. CANCER RESEARCH. 2020. 80. 4
  • Jun Masuda, Junji Tsurutani, Norikazu Masuda, Manabu Futamura, Koji Matsumoto, Kenjiro Aogi, Masato Takahashi, Hiroji Iwata, Tsutomu Iwasa, Toru Mukohara, et al. Phase II study of nivolumab in combination with abemaciclib plus endocrine therapy in patients with hormone receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer (WJOG11418B, NEWFLAME trial). CANCER RESEARCH. 2020. 80. 4
  • Yukinori Ozaki, Toru Mukohara, Junji Tsurutani, Masato Takahashi, Koji Matsumoto, Manabu Futamura, Norikazu Masuda, Shigehisa Kitano, Kenichi Yoshimura, Hironobu Minami, et al. A multicenter phase II study evaluating the efficacy of nivolumab plus paclitaxel plus bevacizumab triple-combination therapy as a first-line treatment in patients with HER2-negative metastatic breast cancer: WJOG9917B NEWBEAT trial. CANCER RESEARCH. 2020. 80. 4
もっと見る
学位 (1件):
  • 博士(保健学) (東京大学)
経歴 (5件):
  • 2020/01/01 - 広島大学 病院 教授
  • 2019/08/01 - 2019/12/31 広島大学 病院総合医療研究推進センター 特任教授
  • 2013/04/01 - 2014/07/31 神戸大学 医学部付属病院 特命准教授
  • 2008/05/01 - 2013/03/31 京都大学 探索医療センター 特別教育研究助教
  • 2005/04/01 - 2008/04/30 厚生労働技官 研究員
※ J-GLOBALの研究者情報は、researchmapの登録情報に基づき表示しています。 登録・更新については、こちらをご覧ください。

前のページに戻る